Base TVL doubles in a month as pundits tip memecoins to drive adoption

Moderna's CEO is highly confident about the prospects of the personalized mRNA cancer vaccine intismeran autogene, stating that it will play a role in more cancers beyond melanoma and drawing parallels with Merck's blockbuster drug Keytruda. Jefferies warns that cross-indication replication is still inconclusive; Citi maintains a "sell" rating, pointing out that commercial application remains limited, with critical issues such as patient suitability, manufacturing, and overall survival data yet to be addressed.

As Morgan Stanley remains bullish on the stock market, recent market trends have precisely demonstrated the strong rebound momentum of tech stocks dominated by the semiconductor sector. The Philadelphia Semiconductor Index rose by 0.44% on October 23rd and further increased by 2.82% on the 26th.

The Anthropic prospectus reveals several highlights: a large-scale enterprise customer base with over 1,900 customers generating more than one million dollars in revenue; as of June 2026, revenue has increased by 1,368% year over year, far surpassing the growth rate of computing costs; positive operating cash flow; and all seven co-founders remain with the company. The company also acknowledges risks, including concentrated supply from TSMC and potential memory chip shortages as significant concerns. October ARR data will be additionally disclosed in a revised version of the document.

Broadcom has reached a $63 billion deal with Bank of America, Blackstone Group, Citigroup, and Morgan Stanley to provide funding for the purchase of chips for AI model developer Anthropic PBC. The transaction is conducted through a newly established special purpose company, which has secured financial commitments from these firms to purchase Broadcom chips and lease them to Anthropic.